Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Key facts

Sponsor

University of California, San Francisco

Principal Investigator

Sabine Mueller, MD, PhD

University of California, San Francisco

Intervention

Metformin(drug)

Enrollment

30 enrolled

Eligibility

1-39 years · All sexes

Timeline

2026 – 2030

Study locations (1)

• University of California, San Francisco, San Francisco, California, United States

Collaborators

The Lilabean Foundation, Inc. · Pediatric Neuro-Oncology Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ependymal tumor

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT03698994
  Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
  National Cancer Institute (NCI)

See all trials for Ependymal tumor →